Table 1.

Features of SPAF III trial participants according to eGFRa

FeatureAll SPAF III Participants Not Assigned to Adjusted-Dose WarfarinHigh-Risk Randomized Trial Participantsb
eGFR ≥60 (n = 859)eGFR 30 to 59 (n = 538)PeGFR ≥60 (n = 501)eGFR 30 to 59 (n = 516)P
Age, mean (years)6773<0.017074<0.01
Male (%)75690.0263590.20
Race (%)0.560.66
    Caucasian93949292
    African American3255
    Hispanic3232
    Other1211
Hypertension (%)4962<0.0164730.02
Diabetes (%)12170.0316200.14
Heart failure (%)18260.0141460.14
Coronary artery disease (%)1730<0.012737<0.01
Prior stroke/TIA (%)1119<0.0137390.54
Paroxysmal AF (%)25200.0319150.10
CHADS2 score (%)<0.01<0.01
    0321743
    136312716
    2+32526881
Serum creatinine, mean (mg/dl)1.01.3<0.0011.01.3<0.01
Mean eGFR (ml/min per 1.73 m2)76507449
  • SPAF, Stroke Prevention in Atrial Fibrillation; eGFR, estimated GFR in ml/min per 1.73 m2 (13); TIA, transient ischemic attack; AF, atrial fibrillation.

  • a 30 participants with eGFR<30 ml/min per 1.73 m2 are not considered.

  • b There were no significant differences in patient features between randomized treatment arms in stage 3 chronic kidney disease (CKD) patients (see Supplementary Table 1).